Literature DB >> 27806226

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Scott Cohen1, Cherylyn Beckey2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27806226     DOI： 10.1056/NEJMc1611289

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs.

Authors:  Takeshi Kurose; Yoshiyuki Hamamoto; Yutaka Seino
Journal:  J Diabetes Investig       Date:  2017-03-30       Impact factor: 4.232

Review 2.  Changes in Myocardial Metabolism Preceding Sudden Cardiac Death.

Authors:  J Snyder; R Zhai; A I Lackey; P Y Sato
Journal:  Front Physiol       Date:  2020-06-16       Impact factor: 4.566

Review 3.  Postprandial Glucose Spikes, an Important Contributor to Cardiovascular Disease in Diabetes?

Authors:  Nordin M J Hanssen; Michael J Kraakman; Michelle C Flynn; Prabhakara R Nagareddy; Casper G Schalkwijk; Andrew J Murphy
Journal:  Front Cardiovasc Med       Date:  2020-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.